MetLife Investment Management
LFCR icon

MetLife Investment Management’s Lifecore Biomedical LFCR Stock Holding History

MetLife Investment Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.1K Buy
+15,257
New +$76.9K ﹤0.01% 2813
2026
Q1 		– Sell
-10,660
Closed -$87.2K – 2814
2025
Q4 		$87.2K Sell
10,660
-5,835
-35% -$43.2K ﹤0.01% 2651
2025
Q3 		$121K Buy
16,495
+1,277
+8% +$9.66K ﹤0.01% 2561
2025
Q2 		$124K Buy
15,218
+4,431
+41% +$29.9K ﹤0.01% 2434
2025
Q1 		$75.9K Sell
10,787
-3,726
-26% -$23.2K ﹤0.01% 2627
2024
Q4 		$108K Buy
+14,513
New +$92.7K ﹤0.01% 2586
2023
Q2 		– Sell
-7,378
Closed -$27.9K – 2968
2023
Q1 		$27.9K Sell
7,378
-7,495
-50% -$41.8K ﹤0.01% 2761
2022
Q4 		$96.4K Hold
14,873
– – ﹤0.01% 2608
2022
Q3 		$132K Buy
14,873
+3,034
+26% +$30.9K ﹤0.01% 2540
2022
Q2 		$118K Sell
11,839
-3,171
-21% -$31.4K ﹤0.01% 2645
2022
Q1 		$174K Buy
15,010
+12,372
+469% +$138K ﹤0.01% 2443
2021
Q4 		$29.3K Sell
2,638
-7,356
-74% -$71.4K ﹤0.01% 2480
2021
Q3 		$92.1K Buy
+9,994
New +$109K ﹤0.01% 2473
2021
Q1 		– Sell
-12,181
Closed -$132K – 2326
2020
Q4 		$132K Buy
12,181
+78
+0.6% +$806 ﹤0.01% 2176
2020
Q3 		$118K Hold
12,103
– – ﹤0.01% 2143
2020
Q2 		$96.3K Hold
12,103
– – ﹤0.01% 2267
2020
Q1 		$105K Hold
12,103
– – ﹤0.01% 2047
2019
Q4 		$137K Buy
12,103
+6,649
+122% +$70.8K ﹤0.01% 2176
2019
Q3 		$59.3K Sell
5,454
-8,556
-61% -$93.1K ﹤0.01% 2323
2019
Q2 		$131K Sell
14,010
-28,020
-67% -$283K ﹤0.01% 2256
2019
Q1 		$516K Buy
42,030
+28,020
+200% +$342K ﹤0.01% 2028
2018
Q4 		$166K Hold
14,010
– – ﹤0.01% 2010
2018
Q3 		$202K Hold
14,010
– – ﹤0.01% 2075
2018
Q2 		$209K Hold
14,010
– – ﹤0.01% 1900
2018
Q1 		$183K Hold
14,010
– – ﹤0.01% 1936
2017
Q4 		$177K Buy
+14,010
New +$177K ﹤0.01% 1992

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

MetLife Investment Management's LFCR Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Lifecore Biomedical (LFCR) in Q2 2026: 15,257 shares worth $80.1K. The stake represents ﹤0.01% of the portfolio and ranks #2813 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in LFCR as recently as Q4 2025.

MetLife Investment Management first reported a position in LFCR in Q4 2017 and has held it in 26 quarters since. The position peaked at $516K in Q1 2019. 98 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • MetLife Investment Management held 15,257 shares of Lifecore Biomedical worth $80.1K as of Q2 2026.
  • Lifecore Biomedical was a new MetLife Investment Management position in Q2 2026.
  • Lifecore Biomedical made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2813 holding.
  • MetLife Investment Management first reported a position in Lifecore Biomedical in Q4 2017 and has held it in 26 quarters since.
  • MetLife Investment Management's Lifecore Biomedical position peaked at $516K in Q1 2019.
  • 98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.